

Ofir Wolach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6540580/publications.pdf>

Version: 2024-02-01

86
papers

1,813
citations

430874

18
h-index

289244

40
g-index

87
all docs

87
docs citations

87
times ranked

3091
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, . | 12.4 | 299 |
| 2 | Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. <i>Cancer Discovery</i> , 2016, 6, 368-381. | 9.4 | 215 |
| 3 | Late-Onset Neutropenia After Rituximab Treatment. <i>Medicine (United States)</i> , 2010, 89, 308-318. | 1.0 | 137 |
| 4 | How I treat mixed-phenotype acute leukemia. <i>Blood</i> , 2015, 125, 2477-2485. | 1.4 | 126 |
| 5 | Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatricâ€inspired regimens: Systematic review and metaâ€analysis. <i>American Journal of Hematology</i> , 2012, 87, 472-478. | 4.1 | 118 |
| 6 | Lymphoma and Leukemia Cells Possess Fractal Dimensions That Correlate with Their Biological Features. <i>Acta Haematologica</i> , 2008, 119, 142-150. | 1.4 | 104 |
| 7 | Neutropenia after rituximab treatment. <i>Current Opinion in Hematology</i> , 2012, 19, 32-38. | 2.5 | 58 |
| 8 | Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agentsâ€a multicenter historical prospective study. <i>Annals of Hematology</i> , 2019, 98, 1927-1932. | 1.8 | 56 |
| 9 | Leucocyte adhesion deficiencyâ€A multicentre national experience. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13047. | 3.4 | 54 |
| 10 | Autoimmunity and Inflammation in Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 2016, 136, 108-117. | 1.4 | 45 |
| 11 | Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. <i>Current Opinion in Hematology</i> , 2017, 24, 139-145. | 2.5 | 44 |
| 12 | Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker. <i>British Journal of Cancer</i> , 2017, 117, 353-357. | 6.4 | 38 |
| 13 | Venetoclax is safe and efficacious in relapsed/refractory AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 2221-2225. | 1.3 | 30 |
| 14 | Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias. <i>European Journal of Haematology</i> , 2018, 101, 297-304. | 2.2 | 27 |
| 15 | Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative diseaseâ€a single center case series. <i>Bone Marrow Transplantation</i> , 2021, 56, 1031-1037. | 2.4 | 25 |
| 16 | Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric Bâ€cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27898. | 1.5 | 22 |
| 17 | Variable Clinical expressivity of STAT3 Mutation in Hyperimmunoglobulin E Syndrome: Genetic and Clinical Studies of Six Patients. <i>Journal of Clinical Immunology</i> , 2014, 34, 163-170. | 3.8 | 21 |
| 18 | Blinatumomab for the Treatment of Philadelphia Chromosomeâ€Negative, Precursor B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 4262-4269. | 7.0 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. <i>American Journal of Hematology</i> , 2021, 96, 790-795. | 4.1 | 20 |
| 20 | Optimal therapeutic strategies for mixed phenotype acute leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 95-102. | 2.5 | 19 |
| 21 | Safety and efficacy of blinatumomab: a real world data. <i>Annals of Hematology</i> , 2020, 99, 835-838. | 1.8 | 19 |
| 22 | Current challenges and opportunities in treating adult patients with Philadelphiaâ€negative acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 705-723. | 2.5 | 18 |
| 23 | Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hematologic patients: Randomized controlled trial. <i>American Journal of Hematology</i> , 2014, 89, 243-248. | 4.1 | 16 |
| 24 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. <i>Clinical Microbiology and Infection</i> , 2018, 24, 749-754. | 6.0 | 15 |
| 25 | Risk factors for mortality due to <i>Acinetobacter baumannii</i> bacteremia in patients with hematological malignancies â€ a retrospective study. <i>Leukemia and Lymphoma</i> , 2019, 60, 2787-2792. | 1.3 | 15 |
| 26 | Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. <i>Clinical Microbiology and Infection</i> , 2022, 28, 303.e1-303.e4. | 6.0 | 15 |
| 27 | Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphiaâ€negative acute lymphoblastic leukemia in first remission. <i>American Journal of Hematology</i> , 2016, 91, 793-799. | 4.1 | 14 |
| 28 | Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2021, 60, 1335-1341. | 1.8 | 14 |
| 29 | Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. <i>Annals of Hematology</i> , 2022, 101, 379-387. | 1.8 | 14 |
| 30 | Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. <i>Annals of Hematology</i> , 2022, 101, 1719-1726. | 1.8 | 14 |
| 31 | Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remissionâ€ a multi-center historical control study. <i>Annals of Hematology</i> , 2019, 98, 2711-2717. | 1.8 | 13 |
| 32 | High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. <i>Hematological Oncology</i> , 2016, 34, 28-35. | 1.7 | 12 |
| 33 | A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2662-2662. | 1.4 | 11 |
| 34 | Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 119. | 3.7 | 10 |
| 35 | Late onset neutropenia after rituximab and obinutuzumab treatment â€ characteristics of a class-effect toxicity. <i>Leukemia and Lymphoma</i> , 2021, 62, 2921-2927. | 1.3 | 9 |
| 36 | Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study. <i>Hematological Oncology</i> , 2015, 33, 42-47. | 1.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Casting a NET on cancer: the multiple roles for neutrophil extracellular traps in cancer. <i>Current Opinion in Hematology</i> , 2022, 29, 53-62. | 2.5 | 8 |
| 38 | Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. <i>Blood Advances</i> , 2022, 6, 2835-2846. | 5.2 | 8 |
| 39 | Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e343-e348. | 0.4 | 7 |
| 40 | Autologous hematopoietic cell transplantation for AML in first remission – An abandoned practice or promising approach?. <i>Seminars in Hematology</i> , 2019, 56, 139-146. | 3.4 | 6 |
| 41 | Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the Cracks. <i>Acta Haematologica</i> , 2014, 132, 279-291. | 1.4 | 5 |
| 42 | Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. <i>Blood Advances</i> , 2020, 4, 3822-3828. | 5.2 | 5 |
| 43 | Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2747-2754. | 1.3 | 5 |
| 44 | Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative. <i>Blood</i> , 2021, 138, 2328-2328. | 1.4 | 5 |
| 45 | Ethnic groups and high sensitivity C-reactive protein in Israel. <i>Biomarkers</i> , 2008, 13, 296-306. | 1.9 | 4 |
| 46 | Acute Promyelocytic Leukemia with a Smoldering Course Associated with Therapy-Related Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2011, 126, 152-156. | 1.4 | 4 |
| 47 | Increased Activity of Cell Membrane-Associated Prothrombinase, Fibrinogen-Like Protein 2, in Peripheral Blood Mononuclear Cells of B-Cell Lymphoma Patients. <i>PLoS ONE</i> , 2014, 9, e109648. | 2.5 | 4 |
| 48 | Analysis of Chronic Granulomatous Disease in the Kavkazi Population in Israel Reveals Phenotypic Heterogeneity in Patients with the Same NCF1 mutation (c.579G>A). <i>Journal of Clinical Immunology</i> , 2018, 38, 193-203. | 3.8 | 4 |
| 49 | Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication. <i>Acta Haematologica</i> , 2020, 143, 65-68. | 1.4 | 4 |
| 50 | Diarrheal Morbidity During Hematopoietic Cell Transplantation: The Diagnostic Yield of Stool Cultures. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1023-1032. | 4.0 | 4 |
| 51 | Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol. <i>Annals of Hematology</i> , 2022, 101, 581-593. | 1.8 | 4 |
| 52 | Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?. <i>Current Opinion in Hematology</i> , 2015, 22, 123-131. | 2.5 | 3 |
| 53 | Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 685-691. | 2.4 | 3 |
| 54 | Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission. <i>European Journal of Haematology</i> , 2021, 106, 64-71. | 2.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. Hemato, 2021, 2, 305-328. | 0.6 | 3 |
| 56 | Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management. Scientific Reports, 2021, 11, 11940. | 3.3 | 3 |
| 57 | First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study. Blood, 2020, 136, 27-28. | 1.4 | 3 |
| 58 | Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. Leukemia Research, 2022, 113, 106773. | 0.8 | 3 |
| 59 | The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1977-1979. | 1.3 | 2 |
| 60 | Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment. Leukemia and Lymphoma, 2020, 61, 2708-2713. | 1.3 | 2 |
| 61 | Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients â€œ a multicenter retrospective observational study. Leukemia and Lymphoma, 2021, 62, 1-7. | 1.3 | 2 |
| 62 | Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. Blood, 2020, 136, 26-28. | 1.4 | 2 |
| 63 | Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation. Blood, 2015, 126, LBA-4-LBA-4. | 1.4 | 2 |
| 64 | Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative. Blood, 2021, 138, 1271-1271. | 1.4 | 2 |
| 65 | Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. Annals of Hematology, 2020, 99, 2939-2945. | 1.8 | 1 |
| 66 | Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.. Journal of Clinical Oncology, 2021, 39, 7007-7007. | 1.6 | 1 |
| 67 | Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 5899-5899. | 1.4 | 1 |
| 68 | Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation. Blood, 2016, 128, 633-633. | 1.4 | 1 |
| 69 | Adolescents and Young Adults with Acute Lymphoblastic Leukemia Have Better Outcomes When Treated with Pediatric-Inspired Regimens - Systematic Review and Meta-Analysis of Comparative Trials. Blood, 2011, 118, 2591-2591. | 1.4 | 1 |
| 70 | Autoimmune and Inflammatory Manifestations Associated with Acute Myeloid Leukemia with Trisomy 8 â€œ Case Series and Review of the Literature.. European Journal of Haematology, 2021, , . | 2.2 | 1 |
| 71 | Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation. Blood, 2021, 138, 4876-4876. | 1.4 | 1 |
| 72 | Leukemic Phase of Histiocytic Sarcoma of the Digestive System: A Rare Manifestation of a Rare Disease. Acta Haematologica, 2021, 144, 229-235. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | From the Editor's Desk: Publishing in Times of a Pandemic. <i>Acta Haematologica</i> , 2021, 144, 473-475. | 1.4 | 0 |
| 74 | Limited PET-CT May Be Adequate for Interim and End of Therapy Response Assessment in Patients with Early Stage Hodgkin and Aggressive Non-Hodgkin Lymphoma - A Retrospective Single Center Study. <i>Blood</i> , 2011, 118, 1562-1562. | 1.4 | 0 |
| 75 | Increased Activity of Prothrombinase Fgl-2 in Peripheral Blood Mononuclear Cells of Patients with B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 2665-2665. | 1.4 | 0 |
| 76 | Continuous Platelet Transfusion Increases Platelet Increment in Refractory Hemato-Oncological Patients - a Single Center Experience. <i>Blood</i> , 2014, 124, 2888-2888. | 1.4 | 0 |
| 77 | Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. <i>Blood</i> , 2015, 126, 1304-1304. | 1.4 | 0 |
| 78 | Risk Factors for Early Mortality in Hemato-Oncological Patients with Carbapenem Resistant <i>Acinetobacter Baumannii</i> (CRAB) Bacteremia. <i>Blood</i> , 2018, 132, 4953-4953. | 1.4 | 0 |
| 79 | Sequential Treatment with FLAG-IDA Salvage Chemotherapy Followed By Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia. <i>Blood</i> , 2018, 132, 5788-5788. | 1.4 | 0 |
| 80 | The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment. <i>Blood</i> , 2019, 134, 5110-5110. | 1.4 | 0 |
| 81 | Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b. <i>Blood</i> , 2019, 134, 179-179. | 1.4 | 0 |
| 82 | Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study. <i>Blood</i> , 2021, 138, 1273-1273. | 1.4 | 0 |
| 83 | Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study. <i>Blood</i> , 2021, 138, 3962-3962. | 1.4 | 0 |
| 84 | Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy. <i>Blood</i> , 2020, 136, 12-13. | 1.4 | 0 |
| 85 | Diarrheal Morbidity in Patients Undergoing Hematopoietic Cell Transplantation - the Diagnostic Yield of Stool Cultures. <i>Blood</i> , 2020, 136, 26-27. | 1.4 | 0 |
| 86 | Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. <i>Blood</i> , 2020, 136, 9-10. | 1.4 | 0 |